Developing breakthrough treatments for fibrotic diseases


Pliant Therapeutics is an early-stage biotechnology company harnessing the therapeutic capabilities of integrin biology and TGF-β signaling to develop breakthrough treatments for fibrotic diseases. By leveraging its powerful product engine, Pliant’s mission is to prevent or even reverse fibrosis, restoring organ function. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression and fuel biomarker discovery for efficient clinical trial design.


Year Invested: 2016
Location: Redwood, Calif.
Visit: www.pliantrx.com

Recent News

November 20, 2018
Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis

November 9, 2018
Pliant Therapeutics Presents Preclinical Data in NASH and PSC at The Liver Meeting 2018

September 6, 2018
Pliant Therapeutics Announces Research Collaboration with Cleveland Clinic to Develop New Disease Targets for Gastrointestinal Fibrosis

Read More News

Associated Team Members

Neil Exter
Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.
Partner